Therapeutic intervention through the inhibition of ERK5 kinase activity may thus have utility in oncology, and a small-molecule inhibitor of ERK5 with anti-proliferative effects in both in vitro and in vivo models of cancer has been reported (Yang et al., 2010 ▸). The gene discussed is MAPK7; the disease is cancer.